Although this is an important observation, the majority of CD8+ tumor-infiltrating lymphocytes in DLBCL have been reported to be terminally exhausted, characterized by high TIM-3 expression, an immunological state associated with poor response to CHOP-based chemotherapy (46). The gene discussed is CD8A; the disease is neoplasm.